FDA panel backs cognitive dysfunction claim for Brintellix

FDA's Psychopharmacologic Drugs Advisory Committee voted 8-2 on Wednesday that H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) provided substantial evidence to support an efficacy claim for Brintellix vortioxetine to treat cognitive dysfunction in adults with major depressive disorder (MDD). The companies market Brintellix in the U.S. to treat MDD in adults. ...